Alan H. Bryce, MD

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.